NoahInsightsWeight loss
Weight loss · 6 min read

Ozempic vs Rybelsus vs Mounjaro: Which GLP-1 Is Right for You?

Choosing a GLP-1 medication for weight loss can feel overwhelming. Three names dominate the conversation in Hong Kong: Ozempic (injectable semaglutide), Rybelsus (oral semaglutide), and Mounjaro (tirzepatide). Each works differently, is administered differently, and produces different results.

Written by our Editorial Team · Medically reviewed by our doctors · Updated 20 Apr 2026

A bowl of vegetable salad

This guide breaks down the clinical evidence, practical differences, and cost considerations to help you have an informed conversation with your doctor.

→ For a complete overview of GLP-1 treatment, see our Complete Guide to GLP-1 Weight Loss in Hong Kong.

1The Basics: What Each Medication Is

Ozempic (Semaglutide — Injectable)

Ozempic is a once-weekly subcutaneous injection that you administer yourself using a pre-filled pen. The active ingredient, semaglutide, is a GLP-1 receptor agonist that mimics the natural GLP-1 hormone your gut produces after meals.

Ozempic was originally approved for type 2 diabetes management. Its use for weight loss in patients without diabetes is considered off-label in some jurisdictions, though semaglutide at the higher 2.4 mg dose (branded as Wegovy) has specific weight-management approval(Based on clinical guidelines and prescribing information).

Available doses: 0.25 mg, 0.5 mg, 1.0 mg, 2.0 mg (weekly)

Rybelsus (Semaglutide — Oral)

Rybelsus contains the same active ingredient as Ozempic — semaglutide — but in a daily oral tablet form. This makes it the world's first oral GLP-1 receptor agonist.

The oral formulation uses a special absorption enhancer (SNAC) to allow the peptide to survive the stomach and be absorbed into the bloodstream. This technology requires strict dosing conditions.

Available doses: 3 mg, 7 mg, 14 mg (daily)

Mounjaro (Tirzepatide — Injectable)

Mounjaro is a once-weekly subcutaneous injection containing tirzepatide, a newer dual-action molecule. Unlike Ozempic and Rybelsus, which target only the GLP-1 receptor, Mounjaro activates both the GLP-1 and GIP receptors.

This dual mechanism is believed to produce greater effects on appetite, metabolism, and fat loss compared to GLP-1 alone.

Available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly)

2Head-to-Head: Clinical Trial Evidence

Weight Loss Efficacy

The most important comparison is how much weight each medication helps patients lose:

MedicationKey TrialDurationAvg. Weight LossPlacebo Loss
Semaglutide 2.4 mg (injectable)STEP 168 weeks14.9%2.4%
Tirzepatide 15 mg (injectable)SURMOUNT-172 weeks22.5%3.1%
Liraglutide 3.0 mg (daily injectable)SCALE56 weeks8.0%2.6%
Semaglutide oral 14 mg——~5-7%(Based on clinical guidelines and prescribing information)—

Key takeaways:

  • Mounjaro (tirzepatide) produces the most weight loss — roughly 50% more than Ozempic at their respective highest doses (Jastreboff AM et al. N Engl J Med. 2022;387(3):205-216. PMID: 35658024).
  • Ozempic/semaglutide injectable delivers strong results — nearly 15% body weight lost on average (Wilding JPH et al. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185).
  • Rybelsus (oral semaglutide) produces more modest weight loss — partly because the maximum approved oral dose (14 mg) delivers lower systemic exposure than the injectable 2.4 mg dose(Based on clinical guidelines and prescribing information).

Proportion of Patients Achieving Significant Loss

Clinical significance is often measured by the percentage of patients who lose ≥5%, ≥10%, or ≥15% of body weight:

ThresholdSemaglutide 2.4 mg (STEP 1)Tirzepatide 15 mg (SURMOUNT-1)
≥5% loss86.4%90.9%
≥10% loss69.1%78.9%
≥15% loss50.5%62.9%
≥20% loss32.0%47.4%

These are remarkable numbers. In the SURMOUNT-1 trial, nearly half of all patients on the highest dose of tirzepatide lost more than 20% of their body weight — a result that approaches bariatric surgery outcomes(Based on clinical guidelines and prescribing information).

3Administration and Convenience

Injection vs Tablet

This is often the deciding factor for many patients:

Ozempic and Mounjaro (weekly injection):

  • Pre-filled pen with a thin, short needle
  • Inject into abdomen, thigh, or upper arm
  • Takes about 30 seconds
  • Rotate injection sites weekly
  • Store in refrigerator (can be at room temperature for up to 28 days after first use)

Rybelsus (daily tablet):

  • Take first thing in the morning on an empty stomach
  • Swallow with no more than 120 mL (half a glass) of plain water
  • Wait at least 30 minutes before eating, drinking, or taking other medications
  • Do not crush, chew, or split the tablet
  • Store at room temperature

The trade-off: Rybelsus is needle-free, but the daily dosing requirements are strict. Many patients find the once-weekly injection less burdensome in practice than a daily medication with rigid rules around eating and drinking.

4Side Effect Comparison

All GLP-1 medications share a similar side-effect profile, primarily gastrointestinal:

Side EffectOzempicRybelsusMounjaro
NauseaVery commonVery commonVery common
DiarrhoeaCommonCommonCommon
VomitingCommonLess commonCommon
ConstipationCommonCommonCommon
Injection-site reactionOccasionalN/AOccasional
Decreased appetiteVery commonCommonVery common

Side effects are generally most pronounced during dose escalation and improve over time. The gradual dose-titration protocols for all three medications are designed to minimise GI discomfort.

Key differences:

  • Mounjaro at the highest dose may produce somewhat more GI side effects, consistent with its greater efficacy(Based on clinical guidelines and prescribing information)
  • Rybelsus has lower rates of nausea compared to injectable semaglutide, likely reflecting its lower bioavailability(Based on clinical guidelines and prescribing information)
  • All three medications carry warnings about pancreatitis and gallbladder disease, though these events are rare

For a detailed side-effect guide: GLP-1 Side Effects: What to Expect and How to Manage Them

5Cost Comparison in Hong Kong

GLP-1 medications are not subsidised by the Hospital Authority for weight management(Based on clinical guidelines and prescribing information). Pricing at private pharmacies and clinics varies:

MedicationApprox. Monthly Cost (HKD)Administration
OzempicHK$1,800–3,000Weekly injection
RybelsusHK$1,500–2,500Daily tablet
MounjaroHK$2,500–4,000Weekly injection

Cost per kilogram lost is a useful way to think about value. Despite being the most expensive per month, Mounjaro's greater efficacy may result in a lower cost per kilogram of weight lost(Based on clinical guidelines and prescribing information).

noah™ offers transparent pricing with medication costs clearly stated before you commit. See: How Much Does GLP-1 Treatment Cost in Hong Kong?

6Which One Should You Choose?

There is no single "best" medication — the right choice depends on your individual circumstances:

Choose Ozempic if:

  • You want strong, well-established weight-loss results
  • You're comfortable with weekly self-injection
  • You want the broadest base of long-term safety data
  • Cost is a consideration (mid-range pricing)

Choose Rybelsus if:

  • You strongly prefer tablets over injections
  • You can commit to the strict daily dosing routine
  • You accept somewhat lower weight-loss results
  • You want the most affordable GLP-1 option

Choose Mounjaro if:

  • Maximum weight loss is your priority
  • You're comfortable with weekly self-injection
  • You're willing to invest more for the most effective option
  • Your doctor recommends dual-receptor therapy

Important Considerations:

  • Medical history matters: Your doctor may recommend one medication over another based on your health conditions, other medications, and risk factors.
  • Starting and switching: It's common to start with one medication and switch if results or tolerability aren't satisfactory.
  • Availability: Supply of GLP-1 medications in Hong Kong can fluctuate. Your doctor will prescribe based on what is currently available(Based on clinical guidelines and prescribing information).

7Frequently Asked Questions

1. Can I switch from Ozempic to Mounjaro?

Yes, switching is possible under medical supervision. Your doctor will determine an appropriate starting dose of the new medication. There may be a brief overlap or washout period depending on your situation.

2. Is oral semaglutide (Rybelsus) as effective as the injection (Ozempic)?

For weight loss specifically, no. The injectable form achieves higher blood levels and greater weight-loss efficacy. However, Rybelsus still produces meaningful weight loss and is a valid option for patients who prefer oral medication(Based on clinical guidelines and prescribing information).

3. Are there any newer GLP-1 medications coming?

Yes. Several next-generation drugs are in development, including oral semaglutide at higher doses, triple-receptor agonists (GLP-1/GIP/glucagon), and amycretin(Based on clinical guidelines and prescribing information). These may offer even greater efficacy in the coming years.

4. Do I need blood tests before starting?

Your doctor will likely request baseline blood work including HbA1c, fasting glucose, lipid panel, liver function, and kidney function(Based on clinical guidelines and prescribing information). This helps establish your metabolic baseline and identify any contraindications.

5. Can I combine GLP-1 medication with other weight-loss treatments?

Some doctors may combine GLP-1 medications with other approaches such as metformin or dietary counselling. However, combining multiple GLP-1 medications is not recommended. Discuss all current medications with your doctor.

8References

  1. 1Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
  2. 2Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
  3. 3Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641
  4. 4Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. PMID: 26132939

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any medication. Treatment suitability is determined by your prescribing doctor based on your individual health profile.

© 2026 noah™. All rights reserved.

This article is for general information only and isn’t medical advice. Talk to a doctor before starting any treatment.

All the way to the end. Questions left over?

That’s what a consult is for. A few minutes of questions, then a registered doctor by text or video.

  • Consult from $200
  • Pay for treatment only if prescribed